[1] Mortier GR, Cohn DH, Cormier-Daire V, et al. Nosology and classification of genetic skeletaldisorders: 2019 revision[J]. Am J Med Genet A, 2019, 179(12):2393-2419. [2] Bonafe L, Cormier-Daire V, Hall C, et al. Nosology and classification of genetic skeletal disorders: 2015 revision[J]. Am J Med Genet A, 2015, 167A(12):2869-2892. [3] Waller DK, Correa A, Vo TM, et al. The population-based prevalence of achondroplasia and than atophoricdysplasia in selected regions of the US[J]. Am J Med GenetA, 2008, 146A(18):2385-2389. [4] Pauli RM. Achondroplasia: A comprehensive clinical review[J]. Orphanet J Rare Dis, 2019, 14(1):1. [5] Wigg K, Tofts L, Benson S, et al. The neuropsychological function of children with achondroplasia[J]. Am J Med Genet A, 2016, 170(11):2882-2888. [6] Pauli RM, Horton VK, Glinski LP, et al. Prospective assessment of risks for cervicomedullary-junction compression in infants with achondroplasia[J]. Am J HumGenet, 1995, 56(3):732-744. [7] Mogayzel PJ, Carroll JL, Loughlin GM, et al.Sleep-disordered breathing in children with achondroplasia[J]. J Pediatr, 1998, 132(4):667-671. [8] Wynn J, King TM, Gambello MJ, et al. Mortality inachondroplasia study: A 42-year follow-up[J]. Am J MedGenet A, 2007, 143A(21):2502-2511. [9] 代伟倩, 顾学范, 余永国. 中国210例软骨发育不全患儿临床遗传特征分析及生长发育曲线探索[J]. 中华儿科杂志, 2020, 58(6):461-467. [10] 张惠琴,陶东英,张静静,等. 软骨发育不全患儿的临床特征及FGFR3基因变异分析[J].中国当代儿科杂志,2022,24(4):405-410. [11] Bober MB, Bellus GA.Hypochondroplasia[J/OL].Gene Reviews, 2020, 5:1-22[2020-12-01].https://www.ncbi.nlm.nih.gov/books/NBK1477/pdf/Bookshelf_NBK1477.pdf. [12] Khan SA, Peracha H, Ballhausen D, et al. Epidemiology of mucopolysaccharidoses[J]. Mol Genet Metab, 2017,121(3):227-240. [13] Giugliani R, Villarreal ML, Valdez CA, et al. Guidelines fordiagnosis and treatment of Hunter syndromeforclinicians in latin America[J]. Genet Mol Biol, 2014, 37(2):315-329. [14] Lin HY, Lin SP, Chuang CK, et al. Incidence of the mucopolysaccharidoses in Taiwan, 1984-2004[J]. Am J Med Genet A, 2009, 149A(5):960-964. [15] Verma, S, Pantoom, S, Petters, J, et al. A molecular genetics view on mucopolysaccharidosis Type Ⅱ[J]. Mutat Res Rev Mutat Res, 2021,788, 108392. [16] D'Avanzo F, Rigon L, Zanetti A, et al.Mucopolysaccharidosis type Ⅱ: One hundred years of research, diagnosis, and treatment[J]. Int J Mol Sci, 2020,21(4)1258. [17] Zhang H, Li JX. Zhang XS, et al.Analysis of the IDS gene in 38 patients with Hunter syndrome: The c.879G&A (p. Gln293Gln) synonymous variation in a female create exonic splicing[J]. PLoS One,2011, 6:1-8. [18] Zhang W, Xie T, Sheng H, et al. Genetic analysis of 63 Chinese patients with mucopolysaccharidosis type Ⅱ:Functional characterization of seven novel IDS variants[J].Clin Chim Acta, 2019, 491: 114-120. [19] Zhang H, Li J, Zhang X, et al. Analysis of the IDS gene in 38patients with Hunter syndrome: The c. 879G>A (p.Gln293Gln) synonymous variation in a female createexonic splicing[J]. PLoS One, 2011, 6(8):e22951. [20] 中华医学会儿科学分会血液学组. 异基因造血干细胞移植治疗黏多糖贮积症儿科专家共识[J]. 中国小儿血液与肿瘤杂志, 2017, 22(5):227-230. [21] Byers PH, Pyott SM.Recessively inherited forms of osteogenesis imperfecta[J].Annu Rev Genet,2012,46:475. [22] 成胜权,石曌玲. 成骨不全的分子遗传学和基因治疗研究进展[J].国际儿科学杂志,2009,36(5):541-544. [23] 成胜权,曹玉红,付蓉,等.兄妹同患成骨不全并双侧苍白球钙化[J].中国当代儿科杂志,2012,14(3):231-232. [24] Clark C.Osteogenesis imperfecta: An overview[J].Nurs Stand, 2001,16(5):47-52. [25] Mari D, Shunichiro T, Daisuke K,et al. Current overview of osteogenesis imperfecta[J]. Medicina,2021, 57, 464. [26] Whyte MP. Hypophosphatasia-aetiology, nosology, pathogenesis, diagnosis and treatment[J]. Nat Rev Endocrinol,2016,12:233. [27] Mornet E, Taillandier A, Domingues C, et al. Hypophosphatasia:A genetic-based nosology and new insights in genotype-phenotype correlation[J].Eur J Hum Genet,2021, 29(2):289-299. [28] Liu MJ, Liu M, Liang XJ,et al. Clinical and genetic characteristics of hypophosphatasia in Chinese children[J]. Orphanet J Rare Dis,2021 ,16(1):159-171. [29] Ridanpáá M, van Eenennaam H, Pelin K, et al. Mutations in the RNA component of RNase MRP cause a pleiotropic human disease, cartilage-hair hypoplasia[J]. Cell,2001,104:195. [30] Lachman RS, Rimoin DL, Spranger J. Metaphyseal chondrodysplasia, Schmid type. Clinical and radiographic delineation with a review of the literature[J]. Pediatr Radiol,1988,18:93. [31] Warman ML,Abbott M,Apte SS,et al. A type X collagen mutation causes Schmid metaphyseal chondrodysplasia[J]. Nat Genet,1993,5:79. [32] Schipani E,Kruse K,Jüppner H.A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia[J]. Science,1995,268:98. [33] Gordon SL, Varano LA, Alandete A, et al. Jansen's metaphyseal dysostosis[J]. Pediatrics,1976,58:556. [34] Posey KL,Hecht JT.The role of cartilage oligomeric matrix protein(COMP) in skeletal diseasd[J].Curr Drug Targets,2008,9(10):869-877. [35] Tufan AC,Satiroglu Tufan NL,et al.Serum or plasma cartilage oligomeric matrix protein concentration as a diagnostic marker in pseudoachondroplasia:Differential diagnosis of a family[J].Eur J Hum Genet,2007,15(10):1023-1028. [36] Briggs MD,Chapman KI.Pseudoachondroplasia and multiple epihyseal dysplasia: Mutation review,molecular interactions,and genotype to phenotype correlations[J].Hum Mutat,2002,19(5):465-478. [37] Kennedy J,Jackson GC,Barker FS,et al.Novel and recurrent mutations in the C-terminal domain of COMP cluster in two distinct regions and result in a spectrum of phenotypes within the pseudoachondroplasia:Multiple epiphyseal dysplasia disease group[J].Hum Mutat,2005,25(6):593-594. [38] Matos-Miranda C,Nimmo G,Williams B,et al. A prospective study of brachytelephalangic chondrodysplasia punctata: identification of arylsulfatase E mutations,functional analysis of novel missense alleles,and determination of potential phenocopies[J].Genet Med,2013,15(8):650-657. [39] White AL,Modaff P, Holland-Morris F, et al. Natural history of rhizomelic chondrodysplasia punctata[J]. Am J Med Genet A, 2003,118A:332. [40] Braverman N, Lin P, Moebius FF, et al. Mutations in the gene encoding 3 beta-hydroxysteroid-delta 8, delta 7-isomerase cause X-linked dominant Conradi-Hünermann syndrome[J]. Nat Genet,1999,22:291. [41] 李林,杜开先,张晓莉,等.ARSE基因突变导致X-连锁隐性遗传点状软骨发育不良的临床表型及基因型分析[J].中国全科医学,2021,24(14):1831-1840. [42] 刘太祥,马晓路,施丽萍,等.新生儿X连锁隐性遗传点状软骨发育不良1例病例报告[J].中国循证儿科杂志,2019,14(5):387-388. [43] 尹婷,王永安,王志伟.一例母源性46,Y,der(X)t(X;Y)(p22;qll)染色体非平衡易位患儿的遗传学分析[J].中华医学遗传学杂志,2021,38(4):376-379. [44] 王彩君,张耀东,康文清,等.总结点状软骨发育不良临床特点及文献复习[J].临床研究,2019,29(2):9-12. |